Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CYCN 
Cyclerion Therapeutics Inc (CYCN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: CYCN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -93.06% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.54M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3893328 | Beta 2.09 | 52 Weeks Range 1.27 - 9.47 | Updated Date 03/31/2025 |
52 Weeks Range 1.27 - 9.47 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-03 | When After Market | Estimate - | Actual 0.2082 |
Profitability
Profit Margin -152.85% | Operating Margin (TTM) 27.8% |
Management Effectiveness
Return on Assets (TTM) -19.76% | Return on Equity (TTM) -30.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3132805 | Price to Sales(TTM) 3.23 |
Enterprise Value 3132805 | Price to Sales(TTM) 3.23 | ||
Enterprise Value to Revenue 1.57 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 2545920 | Shares Floating 1594995 |
Shares Outstanding 2545920 | Shares Floating 1594995 | ||
Percent Insiders 22.64 | Percent Institutions 13.54 |
Analyst Ratings
Rating 5 | Target Price 4 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cyclerion Therapeutics Inc
Company Overview
History and Background
Cyclerion Therapeutics, Inc. (CYCN) was founded in 2019 as a spin-off from Ironwood Pharmaceuticals. It focuses on developing therapies for neurological diseases by modulating the nitric oxide (NO) pathway.
Core Business Areas
- Central Nervous System (CNS) Diseases: Development of therapies for cognitive impairment and other CNS disorders, targeting soluble guanylate cyclase (sGC) stimulation.
Leadership and Structure
Cyclerion Therapeutics is led by its CEO, Peter Hecht, Ph.D.. The company operates with a focused research and development team structure.
Top Products and Market Share
Key Offerings
- CY6463 (Praliciguat): Praliciguat is a soluble guanylate cyclase stimulator being developed for the treatment of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). No market share data currently available as it is still in development. Competitors would be those targeting mitochondrial disfunction such as NeuroBo Pharmaceuticals (NRBO).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investments in research and development. Focus is on novel therapies for underserved neurological conditions.
Positioning
Cyclerion Therapeutics occupies a niche position by focusing on NO pathway modulation. Its success hinges on clinical trial outcomes and regulatory approvals.
Total Addressable Market (TAM)
The TAM for neurological disorders is substantial and expected to grow. Cyclerion's position depends on its ability to develop effective and approved therapies within this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (NO pathway modulation)
- Experienced management team
- Focused research and development efforts
Weaknesses
- Limited product pipeline
- Dependence on clinical trial success
- Significant cash burn rate
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new indications
- Positive clinical trial results
- FDA approval of praliciguat
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- NRBO
Competitive Landscape
Cyclerion faces competition from companies developing therapies for neurological disorders and mitochondrial disfunction. Its advantage lies in its novel approach to the NO pathway.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Cyclerion's historical growth is tied to the advancement of its clinical programs.
Future Projections: Future growth is contingent on successful clinical trials and potential FDA approval. Analyst estimates vary greatly due to the inherent risk in pharmaceutical development.
Recent Initiatives: Recent initiatives focus on advancing CY6463 (Praliciguat) through clinical trials and seeking partnerships.
Summary
Cyclerion Therapeutics is a high-risk, high-reward pharmaceutical company focused on modulating the NO pathway for neurological diseases. Its success depends heavily on the clinical trial outcomes of praliciguat. The company's financial health relies on continued funding, and the competitive landscape is challenging. Positive trial results could significantly enhance its valuation; however, failures could be detrimental.
Similar Companies
NRBO
Neurobo Pharmaceuticals Inc
NRBO
Neurobo Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available, but subject to significant variability)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The pharmaceutical industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyclerion Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-04-02 | CEO, President & Director Dr. Regina Graul Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.cyclerion.com |
Full time employees 1 | Website https://www.cyclerion.com | ||
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.